Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center, discusses findings from the phase 3 NAPOLI 3 trial (NCT04083235) that support the use of NALIRIFOX (irinotecan liposome…
The post ‘Expert Discusses Incorporating NALIRIFOX in Pancreatic Cancer Treatment’ appeared first on DXB Media Group.
